<DOC>
	<DOCNO>NCT01168024</DOCNO>
	<brief_summary>The purpose clinical trial demonstrate efficacy safety Osprey Medical CINCOR™ Contrast Removal System .</brief_summary>
	<brief_title>Contrast Media Reduction Removal Patients With Chronic Kidney Disease ( CKD ) ( PRESERV )</brief_title>
	<detailed_description>The CINCOR™ Catheter System retrieve contrast medium coronary sinus follow injection percutaneous coronary intervention .</detailed_description>
	<criteria>1 . The subject least 18 year age . 2 . The subject candidate therapeutic coronary PCI procedure leave coronary artery and/or branch combination procedure include leave coronary artery/branches AND right coronary artery expect utilize least 50 mL iodinate contrast medium . 3 . The subject baseline eGFR 20 30 mL/min/1.73 m2 inclusive ( determine MDRD equation ( Levey 1993 ) ) ; patient eGFR 30 less equal 60 least two follow : stage III/IV NYHA congestive heart failure , diabetes mellitus , hypertension , age least 75 year . 4 . The subject ( subject 's legal representative ) willing able provide appropriate inform consent . 5 . The subject willing able comply requirement study protocol , include predefined followup evaluation . 1 . The subject unstable renal function ( acute renal failure change serum creatinine &gt; 0.5mg/dL &gt; 25 % within 7 day procedure attribute hydration therapy ) . 2 . The subject require dialysis . 3 . The subject receive contrast medium within 7 day procedure . 4 . The subject receive &gt; 10 ml iodinate contrast medium location coronary artery ( e.g . ventriculography , aortography , renal angiography ) procedure within period 30 day procedure . 5 . The subject require one follow nephrotoxic agent : Aminoglycoside antibiotic , Sulfonamides , Amphotericin B , Levofloxacin , Ciprofloxacin , Rifampin , Tetracycline , Intravenous Acyclovir , Pentamidine , Penicillin Cephalosporins , Cisplatin , Methotrexate , Mitomycin , Cyclosporine , Tacrolimus . 6 . The subject hemoglobin ( Hb ) &lt; 9.5 g/dL within one ( 1 ) week procedure . 7 . The subject hemodynamically unstable require hemodynamic support include intravenous inotropes , vasopressor , type ventricular assist device ( include intraaortic balloon pump , Impella cardiac assist device , TandemHeart VAD , surgically implanted ventricular assist device ) . 8 . The subject acute myocardial infarction within last 24 hour ( define `` Universal Definition Myocardial Infarction ( Thygesen 2007 ) biomarkers cardiac injury stabilize . ( Patients MI within 96 hour index procedure must demonstrate fall biomarkers cardiac injury ) . 9 . The subject follow procedural contraindication 1. leave heart pace lead implant indwell coronary sinus artificial valve pacemaker lead implant right heart within 8 week plan procedure 2. know bleeding diathesis ( e.g . thrombocytopenia [ &lt; 100,000 cells/mm3 ] , heparininduced thrombocytopenia , hemophilia , von Willebrand disease , history intracranial bleeding , gastrointestinal gross genitourinary bleeding ) 3 . The subject currently intravenous anticoagulation discontinue prior procedure 4 . The subject know hypersensitivity heparin bivalirudin aspirin thienopyridine agent iodinate contrast adequately premedicated 5 . The subject active systemic infection 6 . The subject refuse accept blood product ( e.g . Jehovah 's Witness ) 10 . The subject know suspected pregnant , lactate ( woman childbearing potential must negative pregnancy test within 72 hour participate protocol ) . 11 . The subject currently participate another investigational device drug study reach primary endpoint .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Acute Kidney Injury</keyword>
	<keyword>Iodinated Contrast Agent Retrieval</keyword>
	<keyword>Coronary Sinus Cannulation</keyword>
</DOC>